VolitionRx Secures Up to $1.9 Million in Direct Offering
Up to $1.9 million upfront with an additional $2.7 million in potential proceeds from the warrants.
VolitionRx Limited (NYSE AMERICAN: VNRX) is a global leader in epigenetics, and they have recently entered into definitive agreements for a registered direct offering. This announcement comes with the commitment to issue 445,648 shares of common stock priced at $0.5722 per share to various directors and executive officers of the company, known as the Insiders. Moreover, 2,857,389 shares are being offered to other investors, along with accompanying warrants designed to further enhance potential funding.
Investors will find that the offering price for each common stock plus the accompanying warrants is also set at $0.5722 per share. The warrants come in two types: Form A warrants allow the purchase of up to 2,857,389 shares, while Form B warrants permit purchasing up to 1,428,693 shares of common stock. The exercise prices for the A and B warrants are $0.5722 and $0.71525, respectively, and both types are immediately exercisable, expiring five years from issuance.
Notably, the company has opted to sell its securities directly to investors without utilizing an intermediary or placement agent for this offering. Following the close of transactions, expected to occur soon, VolitionRx anticipates generating up to $1.9 million in gross proceeds. This figure is calculated before factoring in estimated expenses connected to the offering. Should the warrants be fully exercised, the potential proceeds could rise significantly, adding around $2.7 million.
VolitionRx plans to allocate these funds strategically to advance their research initiatives and clinical studies. They are focused on enhancing product development and commercialization while also covering general operational costs.
The current offering falls under a shelf registration statement on Form S-3, filed with the Securities and Exchange Commission (SEC). The registration process is crucial as it authorizes the company to offer and sell securities under pre-defined terms over a period. Investors will be able to access a prospectus supplement detailing the offering once it is filed with the SEC.
This approach aligns with Volition's commitment to transparency and regulatory compliance, ensuring that investors are well-informed about the nature of the offerings being executed.
About Volition
VolitionRx is passionately dedicated to pioneering advancements in the field of epigenetics aimed at improving health outcomes. The company focuses on developing innovative blood tests designed to diagnose and monitor various diseases, including several forms of cancer and related conditions.
With a research base in Belgium and additional offices spanning the globe, VolitionRx is committed to sustainability and enhancing patient care through early detection technologies. Their products promise to provide a dual benefit—extending patient life expectancy while enriching life quality.
Media Contacts
For media inquiries, the key contacts are available for further engagement and dialogue. Reach out for discussions about advancements in epigenetics, product launches, or company news.
Frequently Asked Questions
What is the purpose of VolitionRx's recent offering?
The recent offering aims to raise funds for research, development, clinical studies, and product commercialization.
How much is VolitionRx aiming to raise?
VolitionRx seeks to raise approximately $1.9 million initially, with the potential for an additional $2.7 million through the exercise of warrants.
What are the types of warrants involved in this offering?
There are two types of warrants: Form A allows for the purchase of common shares at $0.5722, and Form B allows for purchasing at $0.71525.
Who are the intended recipients of this offering?
This offering targets both insiders of the company and external investors interested in VolitionRx's growth.
What is VolitionRx's primary focus in its operations?
VolitionRx is focused on developing blood tests for the early detection and monitoring of diseases, especially cancer.
